AztraZeneca, the maker of the cholesterol-lowering drug Crestor,
has been accused of false advertising. According to the Food and
Drug Administration (FDA), the drug company has printed misleading
claims about Crestor's safety that state:
-
A medication can be more effective and just as safe" -- this
statement plays down the risks involved in taking a 40 mg dose
of Crestor
-
The FDA has confidence in the safety and efficacy of Crestor" -- this
statement is not only misleading, but it suggest that the FDA
does not feel the drug poses any safety concerns
The drug company's faulty advertisement, which ran in national
and regional publications, also quoted a statement that was "supposedly"
taken directly from the FDA's Web site. The statement read:
"The scientists at the FDA who are responsible for the approval
and ongoing review of Crestor have publicly confirmed that Crestor
is safe and effective, and that the concerns that have been raised
have no medical or scientific basis."
Not only does no such statement exist, the FDA has acknowledged
that Crestor is one of five drugs on the market that pose serious
safety concerns and needs "to be seriously looked at."
In addition, there has been much concern surrounding Crestor since
the day it was approved. Apprehension has also mounted regarding
this drug, as it is the only cholesterol-lowering statin that causes
acute kidney failure and places patients at a high risk of rhabdomyolysis
(a potentially life-threatening muscle disorder).
AztraZeneca has stopped running the disputed advertisements, though
the company continues to fiercely defend the image of Crestor.
USA Today December 23, 2004
New
York Times December 23, 2004
|